Sign in
Taking peopleNo phase

Evaluating the Efficacy and Safety of Contact Lens Lubricant in Rigid Gas Permeable Corneal Contact Lens Wearers

Key facts

Who runs it
Avizor SA
Where
China3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
152 people, planned
Started
27 Jun 2025
Planned end
30 Jun 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • LACRIFRESH OCU-DRY 0.3% OSD
  • Rigid contact lens lubricant
Record updated
29 July 2025

Who can take part

Age
8 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Aged 8 and older, no gender limitation
  • Rigid gas permeable corneal contact lens (OK lens) wearers
  • The best corrected distance visual acuity of framed lenses in both eyes can reach 5.0 (5-Point Scale)
  • Be able and willing to comply with all treatments and follow-ups
  • Be able to understand the purpose of the trial, participate voluntarily and have ICF signed by the subject himself/herself or his/her legal guardian

Who cannot take part

  • Patients who are using or need to use drugs that may cause dry eyes or affect vision and corneal curvature (e.g. immunosuppressant, glucocorticoids, IOP-lowering drugs, low concentration atropine) during the study
  • Subjects who participated in other drug clinical trials within 90 days before screening, and participated in other medical device clinical trials within 30 days
  • Patients with abnormal clinical abnormalities or systemic diseases affecting the eyes that occurred or is occurring before screening and, in the investigator's judgment, preclude the use of corneal contact lenses
  • Patients with some eye diseases that affect contact lens wearing: such as acute or chronic eye diseases, conjunctivitis catarrhalis aestiva, glaucoma, corneal abnormalities, keratoconus, etc
  • Patients with allergies to the components of contact lens or contact lens care solution involved in this trial
  • Patients with a history of intraocular operation
  • Patients with dry eye syndrome or with break up time (BUT) <5s
  • Other conditions for which the investigator judged the patient unsuitable for inclusion
  • Patients with only one eye meeting the inclusion criteria
  • Patients with abnormal IOP (the single eye IOP <10 mmHg or >21mmHg, or the IOP difference of both eyes >5mmHg), obvious fundus abnormalities, examination of corneal endothelial cell (abnormal ≥ Level 4), or slit-lamp examination abnormalities
  • Patients who wore rigid contact lens (including orthokeratology lens) within the past 30 days
  • Patients who are pregnant, nursing or planning to conceive at the enrollment
  • Patients with contraindications for wearing rigid contact lenses or unsuitable for wearing rigid contact lenses as indicated by examination results

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This trial aims to evaluate the safety and effectiveness of LACRIFRESH OCU-DRY 0.3% OSD, a contact lens lubricant produced by AVIZOR, S.A. This clinical trial adopts a Multi-center, randomized, open-label, positive parallel-controlled design in accordance with the principles outlined in the Norms on the Quality Management for the Clinical Trials of Medical Devices issued by the National Medical Products Administration of China.

Read full original descriptionShow less

Meanwhile, following statistical requirements, 152 rigid contact lens wearers are planned to be enrolled after screening and meeting the inclusion criteria. Participants will be randomly assigned to groups and provided with lenses, lubricants, and care solutions accordingly. Clinical follow-up assessments are scheduled at 1 week, 1 month, and 3 months after use.

The primary efficacy indexes are the percentage of patients with binocular comfort score ≥ Level 3 at the 1-month follow-up and the percentage of patients with best corrected distance visual acuity with contact lenses for both eyes ≥5.0 at the 1-month follow-up after using the contact lens lubricant. Secondary efficacy indexes include, best corrected distance visual acuity with lenses, visual acuity with lenses, residual diopter, tear break-up time, uncorrected visual acuity, examination of contact lens fitting status, lens assessment, and contact lens lubricant evaluation during the corresponding follow-up periods. Safety indexes include slit lamp examination, fundus examination, IOP, corneal endothelial cell, adverse events, serious adverse events, device defects that may lead to serious adverse events, other device defects during the corresponding follow-up periods.

The 2 groups in the trial

  • Tested medical deviceTreatment being tested

    LACRIFRESH OCU-DRY 0.3% OSD

    Treatment: LACRIFRESH OCU-DRY 0.3% OSD

  • Control medical deviceExisting treatment, for comparison

    Rigid contact lens lubricant

    Treatment: Rigid contact lens lubricant

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multi-center, Open-Label, Randomized Controlled, Non-Inferiority Clinical Study Evaluating the Efficacy and Safety of Contact Lens Lubricant in Rigid Gas Permeable Corneal Contact Lens Wearers
Record updated
29 July 2025